Literature DB >> 18346026

International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results.

Axel Kroger1, V Pannikar, M T Htoon, A Jamesh, K Katoch, P Krishnamurthy, K Ramalingam, Shen Jianping, Vitthal Jadhav, M D Gupte, P Manickam.   

Abstract

OBJECTIVE: To describe the rationale, design and preliminary results of an open trial of 6 months uniform multi-drug therapy (U-MDT) for all types of leprosy patients assuming a cumulative relapse rate not exceeding 5% over 5 years of follow-up.
METHODS: We intended to recruit 2500 patients each in multi-bacillary (MB) and pauci-bacillary (PB) groups from India (five centres) and China (two centres). Standardized clinical criteria were used to assess skin lesions in the field.
RESULTS: A total of 2912 patients enrolled from November 2003 to May 2007 (India, 2746; China, 166). MB patients constituted 39% and 3% had grade 2 disability. During follow-up, 27 patients (0.9%) developed new lesions. Of these, 78% were on account of reactions. Six patients had clinically confirmed relapse. Clofazimine-related skin pigmentation was short-lived and was acceptable to patients. We analysed data for clinical status of skin lesions. About 2.9% of patients were lost to follow-up; 85.9% completed treatment, of whom 19% had inactive skin lesions. PB patients responded better than MB patients (27%vs. 6%; P < 0.001). At the end of the first (n = 2013) and second year (n = 807) of follow-up post-U-MDT, in 49% and 46% patients, lesions were inactive, respectively (59% and 57% in PB, 37% and 28% in MB; P < 0.001).
CONCLUSION: U-MDT appears to be promising with respect to clinical status of skin lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18346026     DOI: 10.1111/j.1365-3156.2008.02045.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  10 in total

1.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

Review 2.  Newer Drugs for Tuberculosis Prevention and Treatment in Children.

Authors:  Ben J Marais
Journal:  Indian J Pediatr       Date:  2019-02-01       Impact factor: 1.967

3.  Rapid quantitative serological test for detection of infection with Mycobacterium leprae, the causative agent of leprosy.

Authors:  Malcolm S Duthie; Marivic F Balagon; Armi Maghanoy; Florenda M Orcullo; Marjorie Cang; Ronaldo Ferreira Dias; Marco Collovati; Steven G Reed
Journal:  J Clin Microbiol       Date:  2013-12-11       Impact factor: 5.948

Review 4.  Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients.

Authors:  Rossilene Conceição da Silva Cruz; Samira Bührer-Sékula; Maria Lúcia F Penna; Gerson Oliveira Penna; Sinésio Talhari
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

5.  Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.

Authors:  Gerson Oliveira Penna; Samira Bührer-Sékula; Lígia Regina Sansigolo Kerr; Mariane Martins de Araújo Stefani; Laura Cunha Rodrigues; Marcelo Grossi de Araújo; Andrea Machado Coelho Ramos; Ana Regina Coelho de Andrade; Maurício Barcelos Costa; Patricia Sammarco Rosa; Heitor de Sá Gonçalves; Rossilene Cruz; Maurício Lima Barreto; Maria Araci de Andrade Pontes; Maria Lúcia Fernandes Penna
Journal:  PLoS Negl Trop Dis       Date:  2017-07-13

Review 6.  Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis.

Authors:  James A Seddon; H Simon Schaaf
Journal:  Pneumonia (Nathan)       Date:  2016-11-24

7.  International open trial of uniform multidrug therapy regimen for leprosy patients: Findings & implications for national leprosy programmes.

Authors:  Ponnaiah Manickam; Sanjay M Mehendale; Bathyala Nagaraju; Kiran Katoch; Abdul Jamesh; Ramalingam Kutaiyan; Shen Jianping; Shivakumar Mugudalabetta; Vitthal Jadhav; Prabu Rajkumar; Jayasree Padma; Kanagasabai Kaliaperumal; Vijayakumar Pannikar; Padabettu Krishnamurthy; Mohan D Gupte
Journal:  Indian J Med Res       Date:  2016-10       Impact factor: 2.375

8.  Reply of the authors of the Continuing Medical Education article to Dr. Jaison Barreto and Dr. Laila Laguiche.

Authors:  Rossilente Conceiçao Cruz; Samira Bührer-Sékula; Maria Lúcia F Penna; Gerson de Oliveira Penna; Sinésio Talhari
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

9.  Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.

Authors:  Rossilene Conceição da Silva Cruz; Samira Bührer-Sékula; Gerson Oliveira Penna; Maria Elisabete Amaral de Moraes; Heitor de Sá Gonçalves; Mariane Martins de Araújo Stefani; Maria Lúcia Fernandes Penna; Maria Araci de Andrade Pontes; Sinésio Talhari
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

Review 10.  Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?

Authors:  Lehlogonolo N F Maphalle; Bozena B Michniak-Kohn; Modupe O Ogunrombi; Oluwatoyin A Adeleke
Journal:  Children (Basel)       Date:  2022-07-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.